Kemp v. Regeneron Pharmaceuticals, Inc.

CourtDistrict Court, S.D. New York
DecidedJanuary 11, 2023
Docket7:20-cv-02270
StatusUnknown

This text of Kemp v. Regeneron Pharmaceuticals, Inc. (Kemp v. Regeneron Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kemp v. Regeneron Pharmaceuticals, Inc., (S.D.N.Y. 2023).

Opinion

USDC SDNY DOCUMENT UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC #: DATE FILED: 01/11/2023 | Denise Kemp, Plaintiff, Vv. 20 CV 2270 (NSR) OPINION & ORDER Regeneron Pharmaceuticals, Defendant.

NELSON S. ROMAN, United States District Judge Plaintiff Denise Kemp (‘Plaintiff’) brings this action against Defendant Regeneron Pharmaceuticals (“Defendant”), asserting claims for violations of the New York State Human Rights Law (““NYSHRL”) and the Family Medical Leave Act (“FMLA”). Specifically, Plaintiff asserts three claims pursuant to the NYSHRL— discrimination, constructive discharge, and retaliation due to Plaintiff's daughter’s disability. Plaintiff also alleges that Defendant interfered with her right under the FMLA to take twelve (12) weeks of unpaid leave to care for a disabled child. Before the Court is Defendant’s motion for summary judgment, which is brought pursuant to Rule 56 of the Federal Rules of Civil Procedure. (ECF No. 30.) For the following reasons, Defendant’s motion is GRANTED in its entirety. BACKGROUND The facts are gleaned from the Complaint (“Compl.”) (ECF No. 1-4), Defendant’s Rule 56.1 Statement of Undisputed Material Facts (“Def. 56.1”) (ECF No. 31), and Plaintiff's Counter Statement to Defendant’s Rule 56.1 Statement (“PIf Resp”) (ECF No. 40) and are uncontested except where indicated.

Plaintiff’s Hire and Promotions On June 2, 2008, Plaintiff Denise Kemp (“Plaintiff”) began working for Defendant Regeneron (“Defendant”) in its Quality Assurance Department. (Def. 56.1 ¶ 3.) Plaintiff performed well in her initial position as a Senior Good Manufacturing Practices (“GMP”) Auditor and

Defendant rewarded her with promotions, raises, and additional stock option grants. (Id. ¶¶ 3-11.) Specifically, Plaintiff was promoted to Associate Manger, Quality Auditing in 2012, to Manager, Quality Auditing in 2014, and to Senior Manager, Quality Auditing in 2016. (Id. ¶¶ 7-8.) Plaintiff’s 2014 and 2016 promotions were based on the recommendations of Kemp’s direct supervisor, Teresa Rivenburgh (“Rivenburgh”), the Senior Director of Quality Assurance Operations for Defendant. (Id.) When Plaintiff left Defendant’s employ in December 2016, her final annual salary was nearly double her starting salary (representing a rise of $73, 484 increase). (Id. ¶ 11.) Additionally, as of January 2017 Plaintiff had received options to buy 12,6000 shares of Defendant’s common stock, of which she exercised 10,375 shares, representing a more than $2,000,000 W-2 gain. (Id.)

Plaintiff’s Relationship with Rivenburgh Plaintiff and Rivenburgh sat next to one another while both worked in the office, often discussed their personal lives and families, and Rivenburgh met Plaintiff’s children on multiple occasions. (Id. ¶ 14.) Rivenburgh was, accordingly, aware that one of Plaintiff’s daughters suffers from a serious health condition. (Id. ¶ 15.) Although Defendant alleges that Rivenburgh was happy to help Plaintiff care for her daughter, including accompanying Plaintiff’s daughter to doctor appointments, Plaintiff claims that Rivenburgh was not accommodating of Plaintiff’s requests to attend to her daughter’s needs. (Id. ¶ 15; Plf. Resp. ¶ 14.) Plaintiff’s Remote-Work and Potential Move to a New Role Defendant alleges that, beginning in early June of 2016, Plaintiff began to work from home frequently. (Def. 56.1 ¶ 19.) Specifically, Defendant alleges Plaintiff applied for FMLA leave and short-term disability benefits in late March 2016 in connection with her April 2016 surgery and

that Defendant granted these requests. (Id. ¶ 19.) Plaintiff thus took a fully paid leave from April 4, 2016 through May 15, 2016. (Id. ¶ 18.) Additionally, Defendant claims that Plaintiff worked from home fifteen (15) out of the twenty (20) workdays in June and describes the extent of her work from home as “excessive.” (Id. ¶ 23.) Defendant notes that its managers (such as Plaintiff) were expected to be onsite and available in order to address needs that arose throughout the day and to attend meetings in-person., but that they permitted Plaintiff to work remotely at this time. (Id. ¶ 21.) Although Plaintiff does not disagree with the content of Defendant’s allegations regarding her remote work and leave, she seems to dispute their characterization. (Plf. Resp. ¶ 19.) Plaintiff claims that she worked from the hospital for fifteen (15) days in June of 2016 to care for her

daughter while her daughter was in the hospital. (Id. ¶ 6.1.) She further claims that she and her department had always operated remotely, and that working remotely was routine and acceptable for the auditing department generally. (Id.) However, Plaintiff admits that ten days in June of 2016 was an unusually large number of days to not report to the office in a month. (ECF No. 35-1, at 13.) Following Plaintiff’s numerous remote-work days in June 2016, during the first week in July 2016, Rivenburgh told Plaintiff that she needed to increase her visibility in the office and attend meetings in-person. (Def. 56.1 ¶ 27.) Defendant claims that Rivenburgh and her supervisor, Patrice Gilooly (“Gilooly”), thereby created an accommodation for Plaintiff that would enable her to work one day per week from home per week and require Plaintiff to use paid time off (“PTO”) or intermittent FMLA leave for any other day. (Id. ¶ 28.) Although Plaintiff agrees this arrangement was implemented, she describes it as a “limitation” placed on her because Defendant believed she was working from home too frequently; she alleges that both auditors and supervisors regularly

worked from home. (Plf. Resp. ¶ 25.1.) Nevertheless, Plaintiff applied for intermittent FMLA leave in connection with her daughter’s health condition on July 13, 2016; Defendant approved this leave and it was scheduled from August 9, 2016 through February 8, 2017. (Def. Resp. ¶¶ 36-37.) It is also undisputed that Plaintiff’s daughter went to a day program daily, that Kemp had live-in help seven days per week, and, most significantly, that Defendant never denied a request from Plaintiff to leave early, work remotely, or take PTO, whether for medical appointments or other matters. (Id. ¶ 40.) Defendant further alleges that, in July of 2016, Plaintiff approached Gilooly to express her desire to transition to a role with the same status and title as her current role, but which had less managerial responsibilities. (Def. Resp. ¶ 45.) According to Defendant, Plaintiff sought a role that

would: (1) enable her to have a better work/life balance; (2) not have any employees reporting directly to her; and (3) enable her to work with Cory Hutchinson (“Hutchinson”), who at the time was an Executive Director in the Quality Assurance Department. (Id. ¶ 46.) Defendant claims that, over the following months, Plaintiff worked directly with Hutchinson to create a new position of this type and even helped to write and edit the position’s job description. (Id. ¶ 7.) Conversely, Plaintiff alleges that she met with Gilooly to complain that Rivenburgh created the new remote working arrangement and suggested Plaintiff transition into the new role in order to punish Plaintiff for having a sick child. (Plf. Resp. ¶ 41.1.) Plaintiff further claims that although she had control over creating the responsibilities for the new position “to a certain degree,” Gilooly and Hutchinson expected Plaintiff to work in the office four days per week and would not allow her to manage direct reports. (Id. ¶ 41.1.) Moreover, Plaintiff characterized the new position as a “demotion” because she would not have supervisory responsibility. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Spiegel v. Schulmann
604 F.3d 72 (Second Circuit, 2010)
Fincher v. Depository Trust and Clearing Corp.
604 F.3d 712 (Second Circuit, 2010)
Kaytor v. Electric Boat Corp.
609 F.3d 537 (Second Circuit, 2010)
Joyce Bickerstaff v. Vassar College
196 F.3d 435 (Second Circuit, 1999)
Tara C. Galabya v. New York City Board of Education
202 F.3d 636 (Second Circuit, 2000)
Shelley Weinstock v. Columbia University
224 F.3d 33 (Second Circuit, 2000)
Peter Potenza, Clifford Aversano v. City of New York
365 F.3d 165 (Second Circuit, 2004)
Dawn Dawson v. Bumble & Bumble
398 F.3d 211 (Second Circuit, 2005)
Allianz Insurance Company v. Regina Lerner
416 F.3d 109 (Second Circuit, 2005)
Benn v. Kissane
510 F. App'x 34 (Second Circuit, 2013)
Roe v. City of Waterbury
542 F.3d 31 (Second Circuit, 2008)
Sassaman v. Gamache
566 F.3d 307 (Second Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Kemp v. Regeneron Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kemp-v-regeneron-pharmaceuticals-inc-nysd-2023.